Page last updated: 2024-11-04

sulfasalazine and Cardiovascular Diseases

sulfasalazine has been researched along with Cardiovascular Diseases in 7 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"Celecoxib was neutral regarding CVD risk in AS patients."5.46Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017)
"Celecoxib was neutral regarding CVD risk in AS patients."1.46Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017)
"Our study showed that treatment of early rheumatoid arthritis with a combination regime of traditional DMARDs is highly effective in controlling disease activity as well as cardiovascular risk."1.39Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs. ( Biswas, M; Chatterjee, S; Ghosh, A; Ghosh, S; Sarkate, P, 2013)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Mikkelsen, RR1
Hundahl, MP1
Torp, CK1
Rodríguez-Carrio, J1
Kjolby, M1
Bruun, JM1
Kragstrup, TW1
Pers, YM1
Padern, G1
Chatterjee, S1
Sarkate, P1
Ghosh, S1
Biswas, M1
Ghosh, A1
Tam, HW1
Yeo, KJ1
Leong, PY1
Chen, CH1
Li, YC1
Ma, CM1
Wang, YH1
Chiou, JY1
Wei, JC1
Başkan, BM1
Sivas, F1
Aktekin, LA1
Doğan, YP1
Ozoran, K1
Bodur, H1
Cleland, LG1
Caughey, GE1
James, MJ1
Proudman, SM1
van Halm, VP1
Nurmohamed, MT1
Twisk, JW1
Dijkmans, BA1
Voskuyl, AE1

Reviews

1 review available for sulfasalazine and Cardiovascular Diseases

ArticleYear
Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
    European journal of pharmacology, 2022, Jun-15, Volume: 925

    Topics: Animals; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Colchicine; Diabetes Mellitus,

2022

Trials

1 trial available for sulfasalazine and Cardiovascular Diseases

ArticleYear
Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
    The Journal of rheumatology, 2006, Volume: 33, Issue:10

    Topics: Adult; Aged; Antirheumatic Agents; Arachidonic Acid; Arthritis, Rheumatoid; Cardiovascular Diseases;

2006

Other Studies

5 other studies available for sulfasalazine and Cardiovascular Diseases

ArticleYear
Revisiting the cardiovascular risk of hydroxychloroquine in RA.
    Nature reviews. Rheumatology, 2020, Volume: 16, Issue:12

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Arthritis, Rheumatoid; Azithromycin; Ca

2020
Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs.
    The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:8

    Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovasc

2013
Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib

2017
Serum homocysteine level in patients with ankylosing spondylitis.
    Rheumatology international, 2009, Volume: 29, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Biomarkers; Blood Sedimentatio

2009
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    Arthritis research & therapy, 2006, Volume: 8, Issue:5

    Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Case-Control Studies; Fe

2006